A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (FORTUNA)
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele
Sponsor: AstraZeneca
Listed as NCT05809934, this PHASE2 trial focuses on Nonalcoholic Steatohepatitis and remains completed. Sponsored by AstraZeneca, it has been updated 18 times since 2023, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
18 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 13 earlier versions
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
First recorded
Mar 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Acapulco, Mexico , Adana, Turkey (Türkiye) , Almería, Spain , Antalya, Turkey (Türkiye) , Austin, United States , Bangkok, Thailand , Baotou, China , Beijing, China , Boca Raton, United States and 131 more locations